NCT01310179View on ClinicalTrials.gov

Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

July 31, 2014

Conditions
Head and Neck Cancer
Interventions
GENETIC

Ad/PNP and fludarabine monophosphate

Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.

Trial Locations (2)

35233

University of Alabama at Birmingham, Birmingham

37212

Vanderbilt-Ingram Cancer Center, Nashville

Sponsors
All Listed Sponsors
lead

PNP Therapeutics, Inc.

INDUSTRY